Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares fell 1.8% on Monday . The stock traded as low as $47.88 and last traded at $48.65, with a volume of 153,012 shares traded. The stock had previously closed at $49.54.

Several analysts recently issued reports on EGRX shares. Mizuho cut shares of Eagle Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $66.00 to $47.00 in a research note on Monday, June 20th. Royal Bank Of Canada dropped their price objective on shares of Eagle Pharmaceuticals from $94.00 to $78.00 and set an “outperform” rating for the company in a research note on Tuesday, May 10th. Finally, Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $88.94.

The stock’s 50 day moving average is $43.62 and its 200 day moving average is $48.33. The firm’s market capitalization is $756.16 million.

In other Eagle Pharmaceuticals news, major shareholder Proquest Management Llc sold 17,980 shares of the firm’s stock in a transaction on Friday, May 13th. The shares were sold at an average price of $40.72, for a total transaction of $732,145.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

An institutional investor recently raised its position in Eagle Pharmaceuticals stock. Bank of Montreal Can boosted its stake in shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) by 62.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 119,902 shares of the specialty pharmaceutical company’s stock after buying an additional 46,020 shares during the period. Bank of Montreal Can owned about 0.77% of Eagle Pharmaceuticals worth $10,632,000 as of its most recent SEC filing.

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care, orphan diseases and oncology areas. Its commercial products include Argatroban Injection, Ryanodex (dantrolene sodium) for injectable suspension, Diclofenac sodium misoprostol and Docetaxel Injection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.